Cargando…

Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study

Detalles Bibliográficos
Autores principales:	Liu, Xinyang, Qin, Shukui, Wang, Zhichao, Xu, Jianming, Xiong, Jianping, Bai, Yuxian, Wang, Zhehai, Yang, Yan, Sun, Guoping, Wang, Liwei, Zheng, Leizhen, Xu, Nong, Cheng, Ying, Guo, Weijian, Yu, Hao, Liu, Tianshu, Lagiou, Pagona, Li, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759211/ https://www.ncbi.nlm.nih.gov/pubmed/29316953 http://dx.doi.org/10.1186/s13045-017-0545-5

Ejemplares similares

Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
por: Liu, Xinyang, et al.
Publicado: (2017)

Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma
por: Wang, Yonggang, et al.
Publicado: (2022)

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
por: Gong, Jifang, et al.
Publicado: (2016)

Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer
por: Wang, Jinwan, et al.
Publicado: (2015)

Apatinib inhibits tumor growth and angiogenesis in PNET models
por: Wu, Shan, et al.
Publicado: (2018)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
por: Zhou, Ling, et al.
Publicado: (2023)

Apatinib as an optional treatment in metastatic colorectal cancer
por: Li, Aiyi, et al.
Publicado: (2019)

Traditional Chinese medicine Astragalus polysaccharide enhanced antitumor effects of the angiogenesis inhibitor apatinib in pancreatic cancer cells on proliferation, invasiveness, and apoptosis
por: Wu, Jun, et al.
Publicado: (2018)

Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma
por: Yang, Chaoxu, et al.
Publicado: (2018)

Apatinib Combined With Radiotherapy Enhances Antitumor Effects in an In Vivo Nasopharyngeal Carcinoma Model
por: Liu, Shanshan, et al.
Publicado: (2020)

Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma
por: Wang, Chao, et al.
Publicado: (2018)

Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma
por: Peng, Qiu-Xia, et al.
Publicado: (2017)

Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Tan, Aihua, et al.
Publicado: (2023)

Intrauterine exposures, pregnancy estrogens and breast cancer risk: where do we currently stand?
por: Lagiou, Pagona
Publicado: (2006)

Traditional Chinese Medicine Astragalus Polysaccharide Enhanced Antitumor Effects of the Angiogenesis Inhibitor Apatinib in Pancreatic Cancer Cells on Proliferation, Invasiveness, and Apoptosis [Corrigendum]
Publicado: (2022)

Chemoprevention of cancer: current evidence and future prospects
por: Benetou, Vassiliki, et al.
Publicado: (2015)

Dietary assessment methods in epidemiological research: current state of the art and future prospects
por: Naska, Androniki, et al.
Publicado: (2017)

A retrospective six-patient series of apatinib for the treatment of persistent or recurrent carcinoma of the cervix
por: Chen, Chao, et al.
Publicado: (2019)

Apatinib enhances the antitumor effects of radiation in HeLa cell line mouse model of invasive cervical cancer
por: Wang, Yun, et al.
Publicado: (2022)

Apatinib as targeted therapy for sarcoma
por: Li, Feng, et al.
Publicado: (2018)

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
por: Qin, Shukui, et al.
Publicado: (2018)

Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial
por: Liu, Tianshu, et al.
Publicado: (2019)

Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer: A case report
por: Liu, Jin, et al.
Publicado: (2019)

Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial
por: Mei, Kuimin, et al.
Publicado: (2021)

Birth Size and the Pathogenesis of Breast Cancer
por: Lagiou, Pagona, et al.
Publicado: (2008)

Parental Family Structure, Helicobacter Pylori, and Gastric Adenocarcinoma
por: Lagiou, Pagona, et al.
Publicado: (2007)

Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases
por: Xu, Jianping, et al.
Publicado: (2020)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
por: Wang, Jiaqiang, et al.
Publicado: (2023)

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial
por: Shi, Yuankai, et al.
Publicado: (2019)

The synergistic effects of Apatinib combined with cytotoxic chemotherapeutic agents on gastric cancer cells and in a fluorescence imaging gastric cancer xenograft model
por: Feng, Jiuhuan, et al.
Publicado: (2018)

Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways
por: Zhen, Hongchao, et al.
Publicado: (2020)

Secondary pneumothorax as a potential marker of apatinib efficacy in osteosarcoma: a multicenter analysis
por: Tian, Zhichao, et al.
Publicado: (2020)

Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study
por: Tian, Zhichao, et al.
Publicado: (2019)

Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
por: Xu, Rui-Hua, et al.
Publicado: (2017)

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling
por: Cai, Xiaomin, et al.
Publicado: (2020)

Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study
por: Liu, Yanfei, et al.
Publicado: (2023)

Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review
por: Tian, Zhichao, et al.
Publicado: (2021)

Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy
por: Liao, Zhichao, et al.
Publicado: (2020)

Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial
por: Tang, Zhaoqing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_orfplnhaknkjre1f6uu96gkii3